Inhibikase Therapeutics Inc

NASDAQ:IKT   4:00:00 PM EDT
1.39
+0.01 (+0.72%)
4:55:52 PM EDT: $1.35 -0.04 (-2.88%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Inhibikase Therapeutics Inc Stock, NASDAQ:IKT

3350 Riverwood Parkway South East, Suite 1900, Atlanta, Georgia 30339
United States of America
Phone: +1.678.392.3419
Number of Employees: 6
http://www.inhibikase.com

Description

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson�s-related disorders and other diseases of the Abelson Tyrosine Kinases. It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.